Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

InterContinental San Francisco

Nov 05, 2018 7:00 AM - Nov 06, 2018 3:00 PM

888 Howard Street, San Francisco, CA 94103

Real World Evidence Conference

This conference has reached maximum capacity.

Session 3: Use of RWE to Supplement Clinical Trial Design

Session Chair(s)

Sophie  Janssens

Sophie Janssens

Vice President, Global Head of Real World Evidence

UCB Pharma, Inc, Belgium

Mark  Stewart, PhD

Mark Stewart, PhD

Vice President, Science Policy

Friends of Cancer Research, United States

The objective of this session is to understand how RWE has a major role to play in clinical trial design. This session will be divided into the main trials components where RWE can help decision-making: inclusion criteria, comparator (including historical and synthetic arm), endpoints, and estimating effect size. We will address the general concepts, case studies, and provide a regulatory/payer perspective.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Explain how RWE can facilitate clinical trial design
  • Apply learning on how to improve clinical trial design while learning from the case studies
  • Discuss how RWE endpoints facilitated clinical trial development and contribute to regulator/payer decision-making


Jacqueline A. Corrigan-Curay, JD, MD

Use of RWE to Supplement Clinical Trial Design

Jacqueline A. Corrigan-Curay, JD, MD

FDA, United States

Principal Deputy Center Director, Center for Drug Evaluation and Research (CDER)

Khaled  Sarsour, PhD, MPH

Creating External Control Arms for Clinical Trials with RWD: Issues and Implications

Khaled Sarsour, PhD, MPH

Genentech, A Member of the Roche Group, United States

Global Head, RWD Hematology-Oncology

Anuraag  Kansal, PhD

Use of RWE to bridge between endpoints for regulatory and reimbursement audiences

Anuraag Kansal, PhD

Evidera, United States

Senior Research Leader and Director

David  Thompson, PhD

Use of Real-World Data to Supplement Clinical Trial Design:Protocol Feasibility & Patient Identification

David Thompson, PhD

Rubidoux Research LLC, United States

Founder and Principal Consultant

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.